SCHEMBL11943838

SCHEMBL11943838

CCOCCOc1c(N2CCN(C(=O)OCC)CC2)cnn(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.58
▸ LMNA P02545 2/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ USP2 O75604 1/20 0.50
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ HPGD P15428 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NPBWR1 P48145 1/20 0.45
▸ MCHR1 Q99705 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ ATM Q13315 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ APP P05067 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943846 0.94 ALDH1A1 (0.51) ALDH1A1LMNAMAPK1HTTUSP2
SCHEMBL11943836 0.92 ALDH1A1 (0.47) ALDH1A1LMNAMAPK1HTTUSP2
SCHEMBL11943849 0.90 ALDH1A1 (0.52) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL11943840 0.88 KMT2A (0.49) ALDH1A1LMNAHTTUSP2MEN1
SCHEMBL11945073 0.86 ALDH1A1 (0.46) ALDH1A1LMNAHTTUSP2MEN1
SCHEMBL11943833 0.85 SMO (0.48) ALDH1A1LMNAHTTMEN1KMT2A
SCHEMBL11943952 0.84 MAPT (0.44) ALDH1A1LMNAUSP2MEN1KMT2A
SCHEMBL11943814 0.84 NPBWR1 (0.47) ALDH1A1LMNAKMT2ANPBWR1MCHR1
SCHEMBL11943847 0.81 ALDH1A1 (0.43) ALDH1A1LMNAHTTMEN1KMT2A
SCHEMBL11943795 0.78 MEN1 (0.41) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885LMNA 929/4885MAPK1 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback